Key Takeaways
All Americans can legally access EO Care’s clinical cannabis guidance through their digital health platform, regardless of state of residence. This guidance can then be applied using products obtained either under the federal Farm Bill (hemp-derived) or according to applicable state laws, providing a comprehensive, legally compliant solution for both individuals and employers nationwide. April 2026 brought four landmark federal actions — the FDA enforcement-discretion memo, the CMS Beneficiary Engagement Incentive, the CY2027 Medicare Advantage Final Rule, and Schedule III rescheduling — that collectively dismantle the principal regulatory barriers to clinician-guided cannabinoid care. EO Care’s model, grounded in clinical oversight, federal compliance, and evidence-based protocols, is designed precisely for this regulatory environment.
EO Care operates within a legal framework that allows for nationwide delivery of clinical cannabis guidance through its digital health platform while providing access to federally legal hemp-derived products.
Digital Health Guidance Services
- Nationwide Legal Status: EO Care's clinical guidance services are legally permissible in all 50 states.
- Digital Platform Advantage: As a technology and care platform rather than a “plant-touching” entity, EO Care doesn’t require state marijuana licenses. This enables nationwide service delivery through EO’s HIPAA-compliant digital health platform.
Product Options
- Farm Bill Compliance: EO’s hemp-derived Delta-9 THC products (containing ≤0.3% Delta-9 THC by dry weight) are federally legal under the 2018 Farm Bill and can be shipped directly to consumers in most states. Note: In late 2025, Congress updated hemp definitions, switching to a total THC standard of 0.3% and capping hemp-derived cannabinoid products at 0.4 mg of THC per container. This takes effect November 12, 2026, though the effective date may be extended pending further Congressional action. EO Care will remain compliant under the evolving regulatory framework.
- State Law Options: In states with medical or recreational cannabis programs, patients can apply EO’s guidance to locally available products compliant under state law.
- Optional for Employers: Products represent an entirely optional component of EO’s service offering for employer programs. Employers can choose to offer only clinical guidance services while allowing employees to source products independently.
- Medicare Coverage Pathways: Two April 2026 federal actions created new product access channels. 1) The CMS Substance Access Beneficiary Engagement Incentive (April 1) allows participating organizations in ACO REACH, the Enhancing Oncology Model (EOM), and LEAD to provide hemp-derived cannabinoid products to patients, up to $500 per beneficiary per year, under physician direction. 2) The CY2027 Medicare Advantage & Part D Final Rule (April 2) further permits hemp-derived products as a Supplemental Benefit for the Chronically Ill (SSBCI) within Medicare Advantage plans, opening a new channel for employer-sponsored plans.[13][14]
- FDA Enforcement-Discretion (The Makary Letter): On April 1, 2026, FDA Commissioner Marty Makary issued an enforcement-discretion memo stating the FDA will not enforce sections 502(f)(1) or 505 of the FD&C Act against orally administered, hemp-derived CBD products furnished under Medicare (Title XVIII) under physician direction. FDA non-approval has historically been the most-cited reason healthcare institutions decline cannabinoid programs. This memo formally removes that barrier. [12]
Legal Precedents and Opinions
- Insurance Reimbursement: Multiple state appellate courts have ruled that reimbursement for medical cannabis does not violate federal law, establishing precedent that ancillary services like guidance are legally permissible.[1][2][3]
- Workers’ Compensation Precedents: State courts have compelled workers’ compensation insurance boards to pay for medical cannabis when deemed medically necessary for work-related injuries.[9][10][11]
- Legal Counsel Opinion: Foley Hoag’s legal opinion confirms that “nothing in state or federal law presents obstacles to” reimbursement for counseling on medical marijuana treatment.[5]
- Federal Medicare Coverage: The April 2026 CMS Beneficiary Engagement Incentive establishes the first federal precedent for coverage of hemp-derived cannabinoid products within Medicare-linked care programs. This confirms that physician-directed cannabinoid guidance and products can be funded within federal care models — a meaningful parallel to the state court reimbursement precedents above, now at the federal level.[13]
Cannabis Rescheduling Update
- Schedule III: On April 23, 2026, the Department of Justice issued a final order moving FDA-approved cannabis products and state-licensed medical marijuana to Schedule III of the Controlled Substances Act — formally acknowledging accepted medical use and removing the federal-stigma backdrop that prior institutional objections referenced. For decades, Schedule I status made clinical research extremely difficult, blocked prescribing, and created significant liability exposure for clinicians. Schedule III eliminates that framework for qualifying medical programs.[15]
- What’s Still Pending: A broader DEA administrative hearing on whether rescheduling should extend to adult-use cannabis began June 29, 2026, with a conclusion required by July 15, 2026. The outcome will determine whether adult-use programs are eventually brought under Schedule III, arguably the most consequential cannabis policy development in decades. Note that this is not applicable to medical cannabis.
- Impact of Rescheduling: With cannabis now federally recognized as having medical value, Schedule III status provides an impetus for broader clinician involvement, streamlined research, and reduced institutional hesitancy around cannabinoid-based care programs.
1. Hager v. M&K Const., 247 A.3d 864 (2021) - The Supreme Court of New Jersey ruled that a worker’s compensation insurer must cover medical marijuana, concluding that an insurer reimbursing claims for medical marijuana would not violate the Controlled Substances Act.
2. Appel v. GWC Warranty Corp., 291 A.3d 927 (Comm. Court 2023) - A Pennsylvania appeals court concluded that Pennsylvania’s medical marijuana law requires insurers to reimburse patients for medical marijuana if reasonable and necessary for a work-related injury.
3. Appeal of Andrew Panaggio N.H. Comm. Appeals Bd, 174 N.H. 89 (2021) - The New Hampshire Supreme Court concluded that “the CSA does not make it illegal for an insurer to reimburse an employee for his or her purchase of medical marijuana.”
4. Massachusetts General Laws chapter 94I, section 2 - Explicitly permits healthcare providers to “advis[e] a qualifying patient about the risks and benefits of the medical use of marijuana.”
5. Foley Hoag legal memorandum dated August 7, 2023 - Provides analysis concluding that under both state and federal law, there are no obstacles to reimbursement for counseling regarding medical marijuana treatment.
6. Cannabis Regulations Primer, Updated January 29, 2025 - EO Care internal document detailing regulatory changes and outlook.
7. Trump’s public statement on Twitter, September 8, 2024 - “As President, we will continue to focus on research to unlock the medical uses of marijuana to a Schedule 3 drug.”
8. EO Care Intro January 2025 document - References CMS discussion with EO Care to discuss oncology care improvements post-rescheduling.
9. Memo re: Insurance Coverage and Medical Marijuana, August 7, 2023.
10. Hager v. M&K Construction, 247 A.3d 864 (2021) - The New Jersey Supreme Court ordered the workers’ compensation board to reimburse an injured worker for medical marijuana.
11. Appeal of Andrew Panaggio, 174 N.H. 89 (2021) - The New Hampshire Supreme Court ruled that the state’s workers’ compensation board’s denial of reimbursement for medical marijuana was incorrect.
12. FDA Enforcement Discretion Memo, Commissioner Marty Makary, April 1, 2026 - FDA does not intend to enforce sections 502(f)(1) or 505 of the FD&C Act with respect to orally administered, hemp-derived CBD products furnished under Title XVIII under physician direction.
13. CMS Substance Access Beneficiary Engagement Incentive, April 1, 2026 - Up to $500 per beneficiary per year for hemp-derived cannabinoid products in ACO REACH, EOM, and LEAD models.
14. CMS Contract Year 2027 Medicare Advantage and Part D Final Rule, April 2, 2026 - Permits hemp-derived products as SSBCI or clinical program benefit within Medicare Advantage plans.
15. U.S. Department of Justice Final Order, April 23, 2026 - Moves FDA-approved cannabis products and state-licensed medical marijuana to Schedule III of the Controlled Substances Act.
.png)